A Pfizer cast-off could become the company's first marketed drug.
ApexOnco Front Page
Recent articles
Meanwhile, investors await key clinical data.
Meanwhile, Bristol’s other competition in this disease looks set to come from China.
The CDK4/6 inhibitor flunks its phase 3 study – a result that should have been foreseen five years ago.
But investors don't fancy the company's chances, now seeing Aspen-06 as a fluke.
How does the micro-cap biotech now finance a 700-patient phase 3 study?
The group’s Kelun-partnered TROP2 ADC looks like a bargain, but Merck’s pipeline has big shoes to fill.
A mysterious ASCO poster, patient deaths and now clinical hold; where next for BioNTech’s ADC deal?